Nathan J. W. Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nathan J. W. Wu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Katherine E. Dunn
School of Engineering, Institute for Bioengineering, University of Edinburgh, The King’s Buildings, Edinburgh, EH9 3DW, Scotland, U.K.
3 shared publications - Matthew Aquilina
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
3 shared publications - Alan O'CAllaghan
Centre for Genetics and Experimental Medicine, Institute of Genetics and Cancer, Edinburgh, EH4 2XU, Scotland, UK; MRC Human Genetics Unit, University of Edinburgh Institute of Genetics and Cancer, Edinburgh, EH4 2XU, Scotland, UK
2 shared publications Filip Bušić
Institute for Bioengineering, School of Engineering, University of Edinburgh, Edinburgh, UK
2 shared publicationsKiros Kwan
Institute for Bioengineering, School of Engineering, University of Edinburgh, Edinburgh, UK
2 shared publicationsLaura Nicolás-Sáenz
Centre for Genomic & Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
2 shared publications
Latest Publications
- Open Access
- 18 February 2026
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 54 (2) , 195-210
Emerging liquid biopsy tools to analyse cancer biomarkers: electrochemical sensors and extracellular vesicle analysis
Better biomarker analysis technologies can provide improvements in the detection, characterisation and monitoring of cancer and less invasive sampling of blood and other body fluids can improve acceptability and affordability. Here, we discuss these technologies with a specific focus on recent advances in electrochemical sensors, specifically for the analysis of extracellular vesicles (EVs). Widely used biomarker tests with relatively high sensitivity (e.g. ELISAs) are limited by their cost, storage requirements and shelf-life, and ease of use away from centralised facilities. Moreover, their limits of detection (most commonly in the nanomolar to picomolar, with new technologies pushing into the femtomolar range) remain challenged by low abundance biomarkers. Here, we discuss how electrochemical sensor platforms, although often requiring more effort to adapt for new analytes, can provide high sensitivity and direct quantitation at low cost. These platforms are also often simpler to use away from testing facilities. Additionally, we explore how EVs, by protecting nucleic acid and protein cargos from degradation, may facilitate the collective enrichment from blood samples of multiple tumour-derived biomarkers. Continued progress in analysis technologies, alongside a deeper understanding of biomarker biology and clinical value, holds the potential to improve outcomes for the increasing numbers of individuals diagnosed with cancer.
- 18 February 2026
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 54 (2) , 195-210
Open AccessEmerging liquid biopsy tools to analyse cancer biomarkers: electrochemical sensors and extracellular vesicle analysis
Better biomarker analysis technologies can provide improvements in the detection, characterisation and monitoring of cancer and less invasive sampling of blood and other body fluids can improve acceptability and affordability. Here, we discuss these technologies with a specific focus on recent advances in electrochemical sensors, specifically for the analysis of extracellular vesicles (EVs). Widely used biomarker tests with relatively high sensitivity (e.g. ELISAs) are limited by their cost, storage requirements and shelf-life, and ease of use away from centralised facilities. Moreover, their limits of detection (most commonly in the nanomolar to picomolar, with new technologies pushing into the femtomolar range) remain challenged by low abundance biomarkers. Here, we discuss how electrochemical sensor platforms, although often requiring more effort to adapt for new analytes, can provide high sensitivity and direct quantitation at low cost. These platforms are also often simpler to use away from testing facilities. Additionally, we explore how EVs, by protecting nucleic acid and protein cargos from degradation, may facilitate the collective enrichment from blood samples of multiple tumour-derived biomarkers. Continued progress in analysis technologies, alongside a deeper understanding of biomarker biology and clinical value, holds the potential to improve outcomes for the increasing numbers of individuals diagnosed with cancer.
- Open Access
- 5 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
GelGenie: an AI-powered framework for gel electrophoresis image analysis
Gel electrophoresis is a ubiquitous laboratory method for the separation and semi-quantitative analysis of biomolecules. However, gel image analysis principles have barely advanced for decades, in stark contrast to other fields where AI has revolutionised data processing. Here, we show that an AI-based system can automatically identify gel bands in seconds for a wide range of experimental conditions, surpassing the capabilities of current software in both ease-of-use and versatility. We use a dataset containing 500+ images of manually-labelled gels to train various U-Nets to accurately identify bands through segmentation, i.e. classifying pixels as ‘band’ or ‘background’. When applied to gel electrophoresis data from other laboratories, our system generates results that quantitatively match those of the original authors. We have publicly released our models through GelGenie, an open-source application that allows users to extract bands from gel images on their own devices, with no expert knowledge or experience required.
- 5 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessGelGenie: an AI-powered framework for gel electrophoresis image analysis
Gel electrophoresis is a ubiquitous laboratory method for the separation and semi-quantitative analysis of biomolecules. However, gel image analysis principles have barely advanced for decades, in stark contrast to other fields where AI has revolutionised data processing. Here, we show that an AI-based system can automatically identify gel bands in seconds for a wide range of experimental conditions, surpassing the capabilities of current software in both ease-of-use and versatility. We use a dataset containing 500+ images of manually-labelled gels to train various U-Nets to accurately identify bands through segmentation, i.e. classifying pixels as ‘band’ or ‘background’. When applied to gel electrophoresis data from other laboratories, our system generates results that quantitatively match those of the original authors. We have publicly released our models through GelGenie, an open-source application that allows users to extract bands from gel images on their own devices, with no expert knowledge or experience required.
- Open Access
GelGenie: an AI-powered framework for gel electrophoresis image analysis
Gel electrophoresis is a ubiquitous laboratory method for the separation and semi-quantitative analysis of biomolecules. However, gel image analysis principles have barely advanced for decades, in stark contrast to other fields where AI has revolutionised data processing. Here, we show that an AI-based system can automatically identify gel bands in seconds for a wide range of experimental conditions, far surpassing the capabilities of current software. We used a dataset containing 500+ images of manually-labelled gels to train various U-Nets to accurately identify bands through segmentation, i.e. classifying pixels as ‘band’ or ‘background’. When applied to gel electrophoresis data from other laboratories, our system generated results that quantitatively matched those of the original authors. We have publicly released our models through GelGenie, an open-source application that allows users to extract bands from gel images on their own devices, with no expert knowledge or experience required.
Open AccessGelGenie: an AI-powered framework for gel electrophoresis image analysis
Gel electrophoresis is a ubiquitous laboratory method for the separation and semi-quantitative analysis of biomolecules. However, gel image analysis principles have barely advanced for decades, in stark contrast to other fields where AI has revolutionised data processing. Here, we show that an AI-based system can automatically identify gel bands in seconds for a wide range of experimental conditions, far surpassing the capabilities of current software. We used a dataset containing 500+ images of manually-labelled gels to train various U-Nets to accurately identify bands through segmentation, i.e. classifying pixels as ‘band’ or ‘background’. When applied to gel electrophoresis data from other laboratories, our system generated results that quantitatively matched those of the original authors. We have publicly released our models through GelGenie, an open-source application that allows users to extract bands from gel images on their own devices, with no expert knowledge or experience required.
- Open Access
- 18 March 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Reviews in Biomedical Engineering
- Vol. 16 (19373333) , 499-513
The Application of Nanotechnology for Quantification of Circulating Tumour DNA in Liquid Biopsies: A Systematic Review
Technologies for quantifying circulating tumour DNA (ctDNA) in liquid biopsies could enable real-time measurements of cancer progression, profoundly impacting patient care. Sequencing methods can be too complex and time-consuming for regular point-of-care monitoring, but nanotechnology offers an alternative, harnessing the unique properties of objects tens to hundreds of nanometres in size. This systematic review was performed to identify all examples of nanotechnology-based ctDNA detection and assess their potential for clinical use. Google Scholar, PubMed, Web of Science, Google Patents, Espacenet and Embase/MEDLINE were searched up to 23rd March 2021. The review identified nanotechnology-based methods for ctDNA detection for which quantitative measures (e.g. limit of detection, LOD) were reported and biologically relevant samples were used. The pre-defined inclusion criteria were met by 66 records. LODs ranged from 10 zM to 50nM. 25 records presented an LOD of 10fM or below. Nanotechnology-based approaches could provide the basis for the next wave of advances in ctDNA diagnostics, enabling analysis at the point-of-care, but none are currently used clinically. Further work is needed in development and validation; trade-offs are expected between different performance measures e.g. number of sequences detected and time to result.
- 18 March 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Reviews in Biomedical Engineering
- Vol. 16 (19373333) , 499-513
Open AccessThe Application of Nanotechnology for Quantification of Circulating Tumour DNA in Liquid Biopsies: A Systematic Review
Technologies for quantifying circulating tumour DNA (ctDNA) in liquid biopsies could enable real-time measurements of cancer progression, profoundly impacting patient care. Sequencing methods can be too complex and time-consuming for regular point-of-care monitoring, but nanotechnology offers an alternative, harnessing the unique properties of objects tens to hundreds of nanometres in size. This systematic review was performed to identify all examples of nanotechnology-based ctDNA detection and assess their potential for clinical use. Google Scholar, PubMed, Web of Science, Google Patents, Espacenet and Embase/MEDLINE were searched up to 23rd March 2021. The review identified nanotechnology-based methods for ctDNA detection for which quantitative measures (e.g. limit of detection, LOD) were reported and biologically relevant samples were used. The pre-defined inclusion criteria were met by 66 records. LODs ranged from 10 zM to 50nM. 25 records presented an LOD of 10fM or below. Nanotechnology-based approaches could provide the basis for the next wave of advances in ctDNA diagnostics, enabling analysis at the point-of-care, but none are currently used clinically. Further work is needed in development and validation; trade-offs are expected between different performance measures e.g. number of sequences detected and time to result.